Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial
Journal of the American Academy of Dermatology · 2023-06 · 88 (6) · 1300-1307
DOI: 10.1016/j.jaad.2023.01.044 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2023-06. Verfasst von Ben Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospita…. Hauptthemen laut MEDLINE: Paroxetine, Rosacea. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Science Fund for Distinguished Young Scholars.
Abstract (Originalsprache)
BACKGROUND: Patients with refractory erythema of rosacea have limited treatment options. OBJECTIVE: To evaluate the efficacy and safety of a 12-week course of paroxetine for moderate-to-severe erythema of rosacea. METHODS: In a multicenter, randomized, double-blinded, placebo-controlled trial, patients with refractory erythema of rosacea were randomly assigned (1:1) to receive paroxetine 25 mg daily or placebo for 12 weeks. RESULTS: Overall, 97 patients completed the study (paroxetine: 49; placebo: 48). The primary end point was the proportion of participants achieving Clinical Erythema Assessment success (defined as Clinical Erythema Assessment score of 0, 1, or ≥2-grade improvement from baseline) at week 12; this was significantly greater in the paroxetine group than in the placebo group (42.9% vs 20.8%, P = .02). Some secondary end points were met, such as flushing success with point reductions ≥2 (44.9% vs 25.0%, P = .04) and improvement in overall flushing (2.49 ± 3.03 vs 1.68 ± 2.27, P = .047), burning sensation (46.9% vs 18.8%, P = .003), and depression (P = .041). The most reported adverse events associated with paroxetine were dizziness, lethargy, nausea, dyspepsia, and muscle tremors. LIMITATIONS: Only a single-dosage regimen of paroxetine within a 12-week study was evaluated. CONCLUSIONS: Paroxetine is an effective and well-tolerated alternative treatment for moderate-to-severe erythema of rosacea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Resear…
- Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Dermatology, the Affiliated Hospital of North China University of Technology, Tangshan, Hebei, China.
- Department of Dermatology, the Second Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- National Science Fund for Distinguished Young Scholars
Zitieren
APA
Wang, B., Huang, Y., Tang, Y., Zhao, Z., Shi, W., Jian, D., Liu, F., Gao, Q., Wang, P., Yang, J., Li, L., Xie, H., & Li, J. (2023). Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial. Journal of the American Academy of Dermatology, 88(6), 1300-1307. https://doi.org/10.1016/j.jaad.2023.01.044
Vancouver
Wang B, Huang Y, Tang Y, Zhao Z, Shi W, Jian D, et al. Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial. Journal of the American Academy of Dermatology. 2023;88(6):1300-1307. doi:10.1016/j.jaad.2023.01.044
BibTeX
@article{Wang2023,
author = {Wang, Ben and Huang, Yingxue and Tang, Yan and Zhao, Zhixiang and Shi, Wei and Jian, Dan and Liu, Fangfen and Gao, Qiong and Wang, Peiru and Yang, Jie and Li, Lin and Xie, Hongfu and Li, Ji},
title = {Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial},
journal = {Journal of the American Academy of Dermatology},
year = {2023},
volume = {88},
number = {6},
pages = {1300--1307},
doi = {10.1016/j.jaad.2023.01.044}
}
EUVIMED